Vilazodone is used to treat depression in adults. It is an antidepressant and belongs to a group of medicines known as selective serotonin reuptake inhibitors (SSRIs). In addition to potent inhibition of the serotonin transporter, vilazodone acts as a partial agonist at the 5-HT1A receptor, producing a combined mechanism that increases synaptic serotonin levels while modulating 5-HT1A-mediated feedback, which may influence therapeutic onset and anxiolytic effects. The molecule is orally active and is typically dosed once daily with food to enhance absorption. Vilazodone is mainly metabolized by cytochrome P450 enzymes, notably CYP3A4, and undergoes oxidative and conjugative biotransformation to inactive metabolites; elimination is primarily renal and fecal following hepatic metabolism. Clinically important considerations include interaction potential with other serotonergic agents and CYP3A4 modulators, and monitoring for common SSRI adverse effects and for worsening mood or suicidal ideation during treatment initiation and dose changes.
Parent: Vilazodone
Parent: Vilazodone
Parent: Vilazodone
Parent: Vilazodone
Parent: Vilazodone
Synthetic production and stability testing of vilazodone identify several related compounds and degradants including N-desmethyl and N-didemethyl derivatives, hydroxylated and dealkylated products, ring-oxidation products and typical process-related impurities such as residual solvents and trace metal residues. Analytical control is typically performed by HPLC with orthogonal confirmation by LC-MS for structural assignment. Typical specification ranges used in development and quality control limit individual identified impurities to low levels (for example in the range of 0.05 to 0.5 percent w/w depending on whether they are specified or unspecified impurities), with total impurities commonly constrained to about 1.0 percent w/w or lower, and residual solvents controlled to limits set by ICH Q3C. Acceptance criteria and identification thresholds follow ICH Q3A/Q3B principles and are tailored to the maximum daily dose and impurity toxicology data; critical impurities are qualified by safety and genotoxicity assessment and monitored throughout production and shelf life.
Vilazodone inhibits the serotonin transporter which increases extracellular serotonin and concurrently acts as a partial agonist at 5-HT1A receptors, combining SERT blockade with 5-HT1A modulation to alter serotonergic neurotransmission and downstream signaling pathways implicated in depression and anxiety symptoms.
Vilazodone is indicated for the treatment of major depressive disorder in adults; it is prescribed to reduce depressive symptoms and improve functional outcomes under a clinician’s supervision. Typical dosing is titrated to an effective dose, administered with food to optimize absorption, and patients require monitoring for efficacy and adverse effects.
Availability in India depends on local regulatory approvals and commercial launches; vilazodone has been marketed in some regions and generic formulations may be supplied by local manufacturers, but access varies by state and pharmacy. Confirm current availability through local regulatory databases, a licensed pharmacy or a treating physician.
Vilazodone can reduce anxiety symptoms when they accompany major depressive disorder, likely due to 5-HT1A partial agonism in addition to SERT inhibition, but its approval is primarily for depression. Evidence for use as a primary treatment for standalone anxiety disorders is more limited, so clinicians weigh individual clinical data and guidelines when considering it for anxiety management.
